What on-premise clinical AI evidence can support
On-premise deployment can support institutional control, while clinical authority requires evidence tied to the proposed action.
An on-premise deployment establishes where inference occurs. Whether the institution controls the model, data paths, and surrounding environment still depends on the implemented configuration. Neither the deployment label nor infrastructure control establishes what clinical decisions a system may make without clinician review.
A new study evaluated an on-premise clinical agent on MIMIC-IV-derived and external diagnostic benchmarks. The authors distinguish operational trust—control of data, models, and deployment—from decisional trust, assessed through inference-time reliability signals. The evaluation used retrospective, simulated encounters and did not model EHR integration, so it does not establish safety or autonomous diagnostic performance in routine care (Nature Medicine).
That distinction leaves an approval committee with two related but independent questions: what does this deployment control, and what clinical authority does the evidence justify?
Two questions, two evidence boundaries
The infrastructure question belongs to the reviewed configuration. Its answer can describe where inference occurs, who controls the model and deployment environment, what data crosses the boundary, and whether external services remain in the path. A change to the model, host, data path, vendor access, or integration architecture can alter that answer without changing the system’s permitted clinical role.
The authority question belongs to the proposed action and its evaluation. Its answer depends on the patient population, care setting, integration, reliability method, escalation path, and supporting evidence. A change in any of those elements can require a new authority assessment even when the hosting arrangement remains fixed.
This separation is our proposed governance structure, not a protocol reported by the study. It prevents an infrastructure property from being treated as clinical evidence.
Reliability signals do not erase the setting
The secondary report describes institution-controlled infrastructure paired with predefined reliability thresholds for routing cases. It also cautions that benchmark results are not evidence that AI can independently diagnose patients in routine clinical care (ICT&health).
A threshold may inform the design of a routing rule, but only within the limits of the evaluation behind it. The supplied evidence does not show how such a rule performs inside an EHR, under live workflow conditions, or across routine clinical care. A retrospective benchmark could support further evaluation while clinician review remains unchanged; that is an analytical possibility, not a reported study outcome.
The resulting approval record should preserve both boundaries in plain language. The deployment statement can describe the reviewed location of inference, institutional controls, documented data paths, and external dependencies. The authority statement can say that the system was evaluated on retrospective simulated benchmarks and that the study examined reliability signals.
What the record cannot say is equally important: those benchmark findings do not prove autonomous diagnostic safety in routine care. Teams moving toward implementation can carry the two bounded statements into a broader build review, revisiting each when the configuration or the evidence relevant to that decision changes.